N.Y. Education Law § 6817: New drugs

§ 6817. New drugs. 1. Except as otherwise provided in the Federal

Food, Drug and Cosmetic Act, no person shall sell, deliver, offer for

sale, hold for sale, or give away any new drug, unless:

a. an application with respect thereto has become effective, or in the

case of an investigational drug the sponsor has complied with the

applicable requirements, under the Federal Food, Drug, and Cosmetic Act,

or

b. when not subject to such act, such drug has been tested and has not

been found to be unsafe or ineffective for use under the conditions

prescribed, recommended or suggested in the labeling thereof, and, prior

to selling or offering for sale such drug, there has been filed with the

department an application setting forth

(1) full reports of investigations which have been made to show

whether or not such drug is safe and effective for use;

(2) a full list of the ingredients used as components of such drug;

(3) a full statement of the composition of such drug;

(4) a full description of the methods used in, and the facilities and

controls used for, the manufacture, processing and packing of such

drugs;

(5) such samples of such drug and of the ingredients used as

components thereof as the board or secretary may require; and

(6) specimens of the labeling proposed to be used for such drug.

2. An application provided for in paragraph b of subdivision one shall

become effective on the one hundred eightieth day after the filing

thereof, except that if the secretary or board finds, after due notice

to applicant and giving him an opportunity for a hearing, that the drug

is not safe and effective for use under the conditions prescribed,

recommended, or suggested in the proposed labeling thereof, he shall,

prior to the effective date of the application, issue an order refusing

to permit the application to become effective.

3. A drug dispensed on a written or oral prescription of a physician,

dentist, podiatrist or veterinarian (except a controlled substance),

shall be exempt from the requirements of this section if such drug bears

a label containing the name and place of business of the dispenser, the

serial number and date of the prescription, directions for use as may be

stated in the prescription and the name of the physician, dentist,

podiatrist or veterinarian issuing the prescription and the name of the

patient. In addition, such drug shall bear a label containing the

proprietary or brand name of the drug and, if applicable, the strength

of the contents, unless the person issuing the prescription explicitly

states on the prescription, in his own handwriting, that the name of the

drug and the strength thereof should not appear on the label.

4. The board shall promulgate regulations for exempting from the

operation of this section drugs (and with the concurrence of the

commissioner of health, pursuant to article thirty-three of the public

health law, controlled substances) intended solely for investigational

use by experts qualified by scientific training and experience to

investigate the safety and efficacy of drugs and labeled "For

Investigational Use Only". Such regulations may, within the discretion

of the board, among other conditions relating to the protection of the

public health, provide for conditioning such exemptions upon:

a. The submission to the secretary before any clinical testing of a

new drug is undertaken of reports by the manufacturer or sponsor of the

investigation of such drug, of preclinical tests, including tests on

animals of such drug adequate to justify the proposed clincial testing.

b. The manufacturer or the sponsor of the investigation of a new drug

proposed to be distributed to investigators for clinical testing

obtaining a signed agreement from each of such investigators that

patients to whom the drug is administered will be under his personal

supervision, or under the supervision of investigators responsible to

him, and that he will not supply such drug to any other investigator or

to clinics for administration to human beings; and

c. The establishment and maintenance of such records and the making of

such reports to the board by the manufacturer or the sponsor of the

investigation of such drugs of data including, but not limited to,

analytical reports by investigators obtained as the result of such

investigational use of such drug as the board finds will enable it to

evaluate the safety and effectiveness of such drug in the event of the

filing of an application pursuant to subdivision one of this section.

5. This section shall not apply to any drug which was licensed under

the federal virus, serum, and toxin act of July first, nineteen hundred

two (32 Stat. 728) or is licensed under section two hundred sixty-two of

the public health service act of July first, nineteen hundred forty-four

(58 Stat. 682), or under the federal virus, serums, toxins, antitoxins

and analogous products act of March fourth, nineteen hundred thirteen

(37 Stat. 832).